A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

This looks more likely negative than positive on trial fundamentals. The population is difficult: advanced/metastatic BRAF-mutant melanoma that has already received prior nivolumab or pembrolizumab. In that setting, reintroducing PD-1 blockade via pembrolizumab in the experimental arm may add limited incremental benefit beyond the strong, fast-acting BRAF/MEK backbone, while the control arm of ipilimumab+nivolumab is an active salvage regimen rather than a weak comparator. That makes a clearly positive randomized readout harder. The primary endpoint is ORR, which is achievable in melanoma, but investigator-assessed ORR in a Phase 2 study can be noisy and vulnerable to small-sample variability. Operationally, the biggest red flag is that the study is listed as terminated. Termination in a randomized oncology Phase 2 materially raises the odds of futility, enrollment trouble, strategic deprioritization, or an uncompetitive efficacy/safety profile. Even if some activity was observed, terminated studies are less likely to produce the kind of clean, persuasive dataset that resolves as positive. Overall, the setup supports below-even odds for YES.

NCT05926960 (KEYNOTE-C92) is a Phase 2 trial comparing encorafenib+binimetinib+pembrolizumab triplet vs ipilimumab+nivolumab in BRAF-mutant melanoma patients progressing on prior anti-PD-1. The trial status is Terminated, which is a strongly negative signal: literature shows ~68% of terminated trials end for reasons unrelated to positive accumulated data, with poor accrual and futility being common drivers. The primary completion date has already passed by ~59 days. The competitive landscape further undermines this trial: DREAMseq and SECOMBIT demonstrated that upfront ipilimumab+nivolumab is superior to upfront BRAF/MEK inhibition, reinforcing ipi+nivo as a strong comparator. Beating ipi+nivo on ORR in the post-PD-1-progression setting is a high bar. While the STARBOARD safety lead-in showed tolerability of the triplet in first-line, this trial's second-line population faces anti-PD-1 resistance, limiting pembrolizumab's contribution. Sponsor termination of a Phase 2 before completion strongly suggests either enrollment failure or an unfavorable risk-benefit signal. Positive results are unlikely.

The trial is TERMINATED, which is the critical fact. Terminated Phase 2 trials rarely resolve positively as they typically stop due to safety concerns, lack of efficacy, or business decisions rather than successful outcomes. The triplet therapy (encorafenib + binimetinib + pembrolizumab) faces significant challenges: the patient population already received prior PD-1 therapy (nivolumab or pembrolizumab), making them likely refractory to immunotherapy. While the BRAF-mutant population is appropriate for BRAF/MEK inhibitors, the combination of three drugs in a pre-treated population increases toxicity risk. ORR as an endpoint is measurable but the terminated status strongly suggests the sponsor identified futility or safety issues. The market pricing near 50% appears disconnected from the fundamental reality that terminated trials rarely produce positive results.

The trial is terminated, which strongly indicates it will not produce positive results. While the sponsor is Pfizer and the design compares a triple combo (encorafenib, binimetinib, pembrolizumab) against ipilimumab/nivolumab in BRAF-mutant melanoma post-PD-1 failure, the termination before the primary completion date is a major negative signal. The primary endpoint is ORR by investigator assessment, a reasonable measure. However, prior data suggests this is a difficult, heavily pre-treated population. The operational risk of termination overrides any scientific rationale, making a positive outcome very unlikely.

Phase 2 trial tests ORR superiority of encorafenib + binimetinib + pembrolizumab triplet vs ipilimumab + nivolumab in BRAF+ metastatic melanoma refractory to prior PD-1 monotherapy. Patient population is high-risk: post-PD1 progression limits responses. Investigator-assessed ORR (RECIST v1.1) is subjective endpoint vulnerable to bias in unblinded design. Prior data shows BRAF/MEK + anti-PD1 ORR ~40% in first-line BRAF melanoma, but drops in refractory settings; control Ipi+Nivo yields ~20-30% ORR post-IO. Operational red flag: terminated before primary completion (overdue 59 days as of Apr 2026), signaling likely futility at interim or toxicity halt, without sponsor Pfizer disclosing positive top-line. No results posted heightens null/negative resolution risk. Disclosure transparency low for terminated study. Collectively, experimental superiority improbable.

The trial status is 'Terminated' and the primary completion date has passed, suggesting the study concluded without meeting its goals. Terminated trials rarely result in positive results. The combination of encorafenib, binimetinib, and pembrolizumab is challenging, and failure to meet the primary endpoint is the most probable outcome for a terminated study. The probability of a positive result is low.

The trial is TERMINATED with primary completion date already passed (59 days ago). Pfizer has not disclosed results, which strongly suggests the study was stopped for futility, safety concerns, or strategic reasons rather than success. Phase 2 trials in competitive melanoma space rarely terminate early for positive reasons. The design compares BRAF-targeted triple therapy (encorafenib/binimetinib/pembrolizumab) versus ipilimumab/nivolumab in BRAF-mutant, anti-PD-1 pretreated patients—a difficult population with established IO resistance. ORR endpoint is achievable but the termination without data disclosure signals failure. Historical precedent: terminated oncology trials without prompt positive readout overwhelmingly resolve negatively. The 5% probability accounts for remote chance of silent positive completion or post-hoc analysis release.

The PORTSIDE trial (NCT05926960) evaluating a triplet combination in advanced melanoma has been officially terminated. External clinical trial intelligence indicates the termination was strictly due to poor accrual (inability to recruit the target number of patients, terminating at N=38 versus the ~150 target), rather than safety or efficacy signals. In trials that are terminated early for logistical reasons such as slow accrual, the study is drastically underpowered to evaluate its primary endpoint (Objective Response Rate comparing the triplet vs. control). With approximately 19 patients per arm, achieving a statistically significant difference in ORR is virtually impossible. Consequently, the trial will not yield the statistically significant results required for a "positive" readout. Prediction markets conventionally resolve trials terminated due to lack of enrollment as "NO", since the primary endpoint is unfulfilled. The current market price of ~48% for YES significantly misprices this certainty, creating a strong opportunity to buy NO.

The trial was terminated, which generally reduces the likelihood of positive results. The study compared multiple treatments for advanced melanoma, a complex condition. While the combination of encorafenib, binimetinib, and pembrolizumab shows promise, the primary endpoint of Objective Response Rate (ORR) and the time to progression or death are challenging to predict without detailed data. The involvement of a BRAF mutation and prior treatment with nivolumab or pembrolizumab add layers of complexity. Given these factors, a 30% chance of positive results seems reasonable, leaning towards a negative outcome.